ePrivacy and GPDR Cookie Consent by Cookie Consent

LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively.


May 11, 2020


FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer